Roche (RHHBY) expects an increase in Group sales in the mid single digit range. Core earnings per share are targeted to grow in the high single digit range, excluding the impact from the resolution of tax disputes in 2023. Roche expects to further increase its dividend in Swiss francs.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Voyager Therapeutics selloff on UCB news ‘excessive,’ says Leerink
- Genentech announces topline one-year results from ELEVATUM study
- Roche receives FDA approval for Ventana CLDN18 RxDx Assay
- Poseida Therapeutics nominates new CAR-T candidate under Roche collaboration
- Genentech presents two-year data from RAINBOWFISH study at WMS